A new β-tricalcium phosphate with uniform triple superporous structure as a filling material after curettage of bone tumor.
BACKGROUND
A new β-tricalcium phosphate with uniform triple superpore structure, SuperPore(®) (HOYA, Tokyo, Japan), has been in clinical use since 2010. As far as we are aware of, there have been no reported clinical studies using this material. We report on the first clinical cases of benign bone tumor filled with SuperPore(®).


METHODS
We retrospectively evaluated the results for 34 benign bone tumors treated by curettage followed by implantation of the highly purified β-tricalcium phosphates Osferion(®) (Olympus, Tokyo, Japan) or SuperPore(®).


RESULTS
After a mean follow-up of 12 months, none of the patients experienced local recurrence of the tumor or any adverse effects from the filling materials. Radiographically, complete resorption of the material and bone remodeling were achieved in 32 cases. In 17 selected cases with a small bone tumor, the mean period for complete resorption of the filling material was 21 weeks in the Osferion(®) group and 15 weeks in the SuperPore(®) group, with the latter showing a trend for better outcomes.


CONCLUSIONS
SuperPore(®) is a safe and reliable filling substitute for defects following curettage of small bone tumors. Both SuperPore(®) and Osferion(®) gave satisfactory results with good biocompatibility and fast resorption characteristics.
Department of Orthopedic Surgery, Yamaguchi University Graduate School of Medicine, 1-1-1 Minami-Kogushi, Ube, Yamaguchi 755-8505, Japan. muramatu@yamaguchi-u.ac.jp.
Shinichiroh
S
Seto
Keiichi
K
Muramatsu
Takahiro
T
Hashimoto
Yasuhiro
Y
Tominaga
Toshihiko
T
Taguchi
D000293:Adolescent; D000328:Adult; D000368:Aged; D001672:Biocompatible Materials / Q000008:administration & dosage*; D001859:Bone Neoplasms / Q000601:surgery*; D018786:Bone Substitutes; D002130:Calcium Phosphates / Q000008:administration & dosage*; D002648:Child; D003475:Curettage; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000517:prevention & control*; D011379:Prognosis; D012189:Retrospective Studies; D014945:Wound Healing; D055815:Young Adult
D001672:Biocompatible Materials; D018786:Bone Substitutes; D002130:Calcium Phosphates; C485817:beta-tricalcium phosphate
bone remodeling; bone tumor; filling material; resorption; β-Tricalcium phosphate